The diabetes treatments Januvia and Byetta may double patients' risk of pancreatitis, a new study finds.
The diabetes treatments Januvia and Byetta may double patients' risk of pancreatitis, a new study finds. The drugs, sold by Merck and a Bristol-Myers Squibb/AstraZeneca partnership, have been linked to pancreatitis before, but the JAMA Internal Medicine study puts a number to that risk for the first time.
Erstwhile Merck ($MRK) exec Stephen Friend has expanded the reach of his open-science nonprofit Sage Bionetworks via a merger with another nonprofit called the DREAM Project, which rallies researchers to gang up on tricky problems in collaborative competitions.
Just two months after Merck dropped out of a snake-bit biosimilar development program for Enbrel, the pharma giant--which has experienced a number of setbacks in the field--has stepped back up with a new, high-profile partnership, teaming up with a new venture formed by the South Korean conglomerate Samsung and Biogen Idec.
In an effort to bring the first-ever sublingual option for the treatment of severe respiratory allergies to the U.S., French company Stallergenes awaits approval from the FDA for its hay fever treatment Oralair.
Merck agreed to pay $688 million to resolve two securities-fraud lawsuits filed by irate shareholders. Pension funds and other institutional investors alleged that Merck--and Schering-Plough, which Merck bought in 2009--held back key information about the Enhance trial, which tested the combination drug Vytorin against one of its constituent parts, the statin drug Zocor.
A new study published in Clinical Infectious Diseases suggests a link between untreated depression in older adults and decreased effectiveness of the herpes zoster shot.
An upstart tech company that has made foiling drug counterfeiters the heart of its business plan has caught the attention of the entrepreneurial class.
Merck has essentially doubled down on its discovery deal with Ann Arbor, MI-based Lycera, a biotech spinout from the University of Michigan following their own unique pathway to mount a therapeutic assault on autoimmune diseases.
CEOs have been offering up cuts to manufacturing operations as one antidote to sick balance sheets during the most recent round of earnings updates and Merck is among those whittling away.